title: Pharmacological treatment of ADHD and the short and long term effects on sleep.
abstract: There is growing research focusing on the sleep problems of children with attention-deficit/hyperactivity disorder (ADHD) in recent years. High incidence of sleep disorders in children with ADHD may be associated with a substantial impact on their quality of life and exacerbation of ADHD symptoms. The core symptoms of ADHD can be effectively treated by various medications, including methylphenidate (MPH), amphetamine, pemoline, and the newly FDA-approved extended-release α2 adrenergic agonists. However, most of them are known to affect patients' sleep because of their pharmacological actions on dopaminergic and/or noradrenergic release in the central nervous system. Previous studies have found increased incidence of insomnia and sleep disturbances in ADHD children treated with CNS (central nervous system) stimulants. In contrast, recent prospective, double-blind, placebo-controlled trials concluded that MPH, by objective polysomnographic or actigraphic measurements, did not cause significant sleep problems in children or adolescents with ADHD. Given the fact that sleep quality and core symptoms of ADHD are highly correlated, it is imperative that we understand the effects of ADHD medications on sleep while prescribing either CNS stimulants or non-CNS stimulants. Here we will concisely review the pharmacological treatments of ADHD, and provide the relevant data discussing their short- and long-term effects on sleep.
authors.affiliation: Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
authors.forename: Yu-Shu
authors.initials: YS
authors.lastname: Huang
authors.forename: Ming-Horng
authors.initials: MH
authors.lastname: Tsai
authors.forename: Christian
authors.initials: C
authors.lastname: Guilleminault
mesh_terms: D056044:Actigraphy; D000293:Adolescent; D000818:Animals; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D004298:Dopamine / Q000378:metabolism; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D017286:Polysomnography; D011788:Quality of Life; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced / Q000453:epidemiology; D012893:Sleep Wake Disorders / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D004298:Dopamine; D009638:Norepinephrine